Immuron Announces A$5.1M Private Placement to U.S. Fund
Filed with ASX · · 2 pages · English
In the deck
Earlier from Immuron
- Immuron Reports Positive Results in NASH Clinical Trial
- Correction to False and Misleading News Release
- Appendix 4D - Half Year Financial Report - 31 Dec 2017
- Travelan Revenue Grows Significantly in US and Australia
- US Defence Depart Report-Travelan Targets Priority Pathogens
Later from Immuron
- Travelan Sales Continue to Soar in Third Quarter of FY2018
- IMC Preclinical Study Reports Reduction in Colitis Symptoms
- Immuron Announces Board Appointment
- European Patent Gramted for Nash Treatment
- US Department of Defense Research Collaboration Moves Ahead
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron